Login / Signup

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.

Liudmila V FedorovaKirill V LepikNikita P VolkovPolina V KotselyabinaEvgenia S BorzenkovaMarina O PopovaAnastasia V BeynarovichVadim V BaykovAndrey V KozlovIvan S MoiseevNatalia B MikhailovaAlexander D Kulagin
Published in: International journal of clinical oncology (2021)
Combination of Nivo + BV in r/r cHL after nivolumab monotherapy failure is potentially an effective and safe approach.
Keyphrases
  • hodgkin lymphoma
  • combination therapy
  • open label
  • lipopolysaccharide induced
  • lps induced
  • clinical trial
  • multiple myeloma